Premium
Human Amniotic Fluid Derived Stem Cells (hAFSCs) Improve Renal Function in a Rodent Model of Ischemia‐Induced Acute Kidney Injury (AKI)
Author(s) -
Eckman Delrae,
George Sunil,
Abolbahari Mehran,
Wilson Adam,
Jackson John,
Tullot Tony,
Atala Anthony,
Yoo James
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.784.1
Subject(s) - medicine , saline , acute kidney injury , ischemia , creatinine , renal function , urology , nephrology , renal ischemia , kidney , kidney disease , stem cell , anesthesia , surgery , reperfusion injury , pathology , biology , genetics
Background The occurrence of AKI in the US continues to grow and causes significant morbidity and mortality. Recent reports indicate stem cell therapy improves renal dysfunction in rodent models of chemically‐induced AKI. The intent of this study was to assess whether hAFSCs could be used as an effective therapy for ischemia‐induced AKI. Methods: AKI was induced via 1hr bilateral renal ischemia in 3mo, male, nude rats. After ischemia, kidney reperfusion was confirmed for 20min followed by injection of either saline (saline, 0.05ml) or hAFSC (cell, 1.25x10 6 cells/pole) into the upper and lower pole of both kidneys. The surgical incision was closed immediately after saline/cell injection and rats were closely monitored during recovery. Serum creatinine (sCR) was measured 24hr prior to injection (B) and for 7 days post cell/saline injection (d1‐d7). The effect of cell therapy on renal and glomerular structure/integrity, SOD and Caspase‐3 expression was evaluated histologically. Serum and histological assessments were compared to age‐matched control rats (AMC). Results: When compared to saline treated rats, hAFSCs treatment significantly improved sCr (see figure, p<0.05), glomerular integrity (P<0.05), and attenuated SOD1 and Caspase‐3 expression (p<0.01 and p<0.01, respectively).Conclusion These data demonstrate AFSCs have the potential to be used as a therapeutic option for ischemia‐induced AKI.